间充质基质细胞治疗COVID-19相关ARDS:多中心随机双盲试验
STROMA-CoV-2是一项在法国10个中心开展的多中心、双盲、随机、安慰剂对照2b期试验,纳入45例SARS-CoV-2诱导的早期(<96 h)轻至重度ARDS成人。患者随机接受5天内三次静脉输注106个UC-MSCs/kg或安慰剂(0.9% NaCl)。改良意向治疗人群中,主要终点D0至D7的PaO2/FiO2变化在UC-MSCs组与安慰剂组间无显著差异(中位数54.3 vs 25.3;ANCOVA估计治疗效应7.4,95%CI -44.7至59.7;P=0.77)。UC-MSCs组21例中6例(28.6%)、安慰剂组24例中6例(25%)发生严重不良事件,均与UC-MSCs治疗无关。作者认为需要更大规模、更早期纳入ARDS患者的试验进一步评估UC-MSCs疗效。
要点
- 在SARS-CoV-2诱导的早期(<96 h)轻至重度ARDS成人中,D0至D7的PaO2/FiO2变化UC-MSCs组与安慰剂组无显著差异(中位数54.3 vs 25.3;治疗效应7.4,95%CI -44.7至59.7;P=0.77)。
- UC-MSCs组21例中6例(28.6%)、安慰剂组24例中6例(25%)发生严重不良事件,均与UC-MSCs治疗无关。
- 干预方案为5天内三次静脉输注106个UC-MSCs/kg或安慰剂(0.9% NaCl)。
- 作者认为需要更大规模、更早期纳入ARDS患者的试验进一步评估UC-MSCs疗效。
适用人群与场景
- 成人(≥18岁)SARS-CoV-2诱导的早期(<96 h)轻至重度ARDS患者,来自法国10个中心。
处置流程与药物剂量
- 随机接受5天内三次静脉输注106个UC-MSCs/kg或安慰剂(0.9% NaCl)。
研究设计与关键结果
- 多中心、双盲、随机、安慰剂对照2b期试验(STROMA-CoV-2),10个法国中心,筛查107例,纳入45例并随机分析。
- 主要终点D0至D7的PaO2/FiO2变化:UC-MSCs组中位数54.3(IQR -15.5至93.3)vs 安慰剂组25.3(IQR -33.3至104.6);ANCOVA估计治疗效应7.4,95%CI -44.7至59.7;P=0.77。
- 严重不良事件:UC-MSCs组21例中6例(28.6%),安慰剂组24例中6例(25%),均与UC-MSCs治疗无关。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机、安慰剂对照2b期试验。
- 局限:作者指出需要更大规模、更早期纳入ARDS患者的试验进一步评估UC-MSCs疗效。
对床旁实践的改变
- 作者认为,对于SARS-CoV-2诱导的早期ARDS成人,静脉输注UC-MSCs与安慰剂相比D0至D7的PaO2/FiO2变化无显著差异;重复输注UC-MSCs在治疗期间及之后(至D28)未伴随严重不良事件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-induced acute respiratory distress syndrome (ARDS) causes high mortality. Umbilical cord-derived mesenchymal stromal cells (UC-MSCs) have potentially relevant immune-modulatory properties, whose place in ARDS treatment is not established. This phase 2b trial was undertaken to assess the efficacy of UC-MSCs in patients with SARS-CoV-2-induced ARDS.
METHODS: This multicentre, double-blind, randomized, placebo-controlled trial (STROMA-CoV-2) recruited adults (≥ 18 years) with SARS-CoV-2-induced early (< 96 h) mild-to-severe ARDS in 10 French centres. Patients were randomly assigned to receive three intravenous infusions of 106 UC-MSCs/kg or placebo (0.9% NaCl) over 5 days after recruitment. For the modified intention-to-treat population, the primary endpoint was the partial pressure of oxygen to fractional inspired oxygen (PaO2/FiO2)-ratio change between baseline (day (D) 0) and D7.
RESULTS: Among the 107 patients screened for eligibility from April 6, 2020, to October 29, 2020, 45 were enrolled, randomized and analyzed. PaO2/FiO2 changes between D0 and D7 did not differ significantly between the UC-MSCs and placebo groups (medians [IQR] 54.3 [- 15.5 to 93.3] vs 25.3 [- 33.3 to 104.6], respectively; ANCOVA estimated treatment effect 7.4, 95% CI - 44.7 to 59.7; P = 0.77). Six (28.6%) of the 21 UC-MSCs recipients and six of 24 (25%) placebo-group patients experienced serious adverse events, none of which were related to UC-MSCs treatment.
CONCLUSIONS: D0-to-D7 PaO2/FiO2 changes for intravenous UC-MSCs-versus placebo-treated adults with SARS-CoV-2-induced ARDS did not differ significantly. Repeated UC-MSCs infusions were not associated with any serious adverse events during treatment or thereafter (until D28). Larger trials enrolling patients earlier during the course of their ARDS are needed to further assess UC-MSCs efficacy in this context.
TRIAL REGISTRATION: NCT04333368. Registered 01 April 2020, https://clinicaltrials.gov/ct2/history/NCT04333368 .
参考来源
- Monsel A, Hauw-Berlemont C, Mebarki M, et al. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit Care. 2022. PMID: 35189925. doi:10.1186/s13054-022-03930-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。